Paclitaxel alters melanogenesis and causes pigmentation in the skin of gynecological cancer patients.
Paula MonteroCelia SanzJose Alejandro Pérez-FidalgoMartín Pérez-LealJavier MilaraJulio CortijoPublished in: Fundamental & clinical pharmacology (2023)
The results suggest that PTX alters pigmentation in patients with no clinically visible manifestations, and these alterations might be driven by its capacity to stimulate melanogenesis on melanocytes through the MITF activation pathway.
Keyphrases